Contributor Since 2010
CombiMatrix is a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques including microarray, standardized, and customized FISH, and high resolution karyotyping.
The company today announced a strategic partnership with Manhattan Labs, an independent clinical laboratory that serves the New York City area. Its emphasis is on women's health, particularly obstetrics and reproductive issues. Manhattan labs will market and distribute in New York City CombiMatrix microarray tests for the miscarriage management testing market.
The agreement between the two firms was directly enabled by the announcement in June that CombiMatrix miscarriage management tests had received conditional approval from the New York State Department of Health for testing on patient samples within New York state.
Miscarriage management testing allows OB/GYN doctors to better determine if there is a genetic cause for a miscarriage or other related events. Microarray testing is believed by many in the industry to be the coming standard of care since it can identify a greater number of possible genetic abnormalities more accurately than currently available technology.
The partnership is a key step for CombiMatrix. First, it shows that microarray testing is indeed becoming more and more accepted as a diagnostic tool in the women's health field. Secondly, it gives the company access into the large New York City market for its leading growth product. For additional information about CombiMatrix and its entire product line, please visit combimatrix.com.
Please see disclaimer on the MissionIR website